Guangzhou Zaiji Medical Technology Co., Ltd.

1) Phase 1: Evaluate the tolerability and safety of MAX-10181 in combination with lenvatinib in patients with advanced solid tumors, and determine the Phase II recommended dose (RP2D) and/or maximum tolerated dose (MTD). 2) Phase 2: Evaluate the preliminary efficacy of MAX-10181 in combination with lenvatinib in patients with advanced solid tumors.

1) To evaluate the safety and tolerability, pharmacokinetics, and recommended combined dose (RP2D) of MAX-10181 combined with temozolomide (TMZ) in patients with recurrent/progressive high-grade glioma (HGG). 2) To evaluate the preliminary efficacy of MAX-10181 combined with TMZ in patients with newly diagnosed glioma.

Primary objectives: 1) Phase I: Evaluate the tolerability and safety of MAX-10181 combined with capecitabine in patients with advanced/metastatic solid tumors, and determine the recommended dose (RP2D) of MAX-10181 combined with capecitabine in different solid tumors. 2) Phase II: Evaluate the preliminary efficacy of MAX-10181 combined with capecitabine in patients with advanced/metastatic solid tumors. Secondary objectives: 1) Evaluate the pharmacokinetic (PK) characteristics of MAX-10181 combined with capecitabine in the treatment of patients with advanced/metastatic solid tumors. 2) Retrospectively analyze the relationship between relevant biomarkers and the anti-tumor effect of MAX-10181 combined with capecitabine.